7.34
+0.08(+1.10%)
Currency In USD
| Previous Close | 7.26 |
| Open | 7.27 |
| Day High | 7.59 |
| Day Low | 7.18 |
| 52-Week High | 17.41 |
| 52-Week Low | 2.24 |
| Volume | 898,647 |
| Average Volume | 1.08M |
| Market Cap | 342.77M |
| PE | -2.08 |
| EPS | -3.53 |
| Moving Average 50 Days | 4.69 |
| Moving Average 200 Days | 4.97 |
| Change | 0.08 |
If you invested $1000 in 4D Molecular Therapeutics, Inc. (FDMT) since IPO date, it would be worth $185.43 as of August 18, 2025 at a share price of $7.51. Whereas If you bought $1000 worth of 4D Molecular Therapeutics, Inc. (FDMT) shares 3 years ago, it would be worth $859.27 as of August 18, 2025 at a share price of $7.51.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
4DMT to Participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
GlobeNewswire Inc.
Aug 06, 2025 12:00 PM GMT
EMERYVILLE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatmen
4DMT Presents Positive 60-Week Results from 4D-150 SPECTRA Clinical Trial in DME and Regulatory Update
GlobeNewswire Inc.
Jul 31, 2025 8:05 PM GMT
4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in visual acuity and anatomic control Phase 3 dose (3E
4DMT Announces Presentations at 43rd Annual Scientific Meeting of the American Society of Retina Specialists
GlobeNewswire Inc.
Jul 24, 2025 12:00 PM GMT
EMERYVILLE, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatmen